Is Taurine a Biomarker in Autistic Spectrum Disorder?

Conference paper
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 975)


Taurine is a sulfur-containing amino acid which is not incorporated into protein. However, taurine has various critical physiological functions including development of the eye and brain, reproduction, osmoregulation, and immune functions including anti-inflammatory as well as anti-oxidant activity. The causes of autistic spectrum disorder (ASD) are not clear but a high heritability implicates an important role for genetic factors. Reports also implicate oxidative stress and inflammation in the etiology of ASD. Thus, taurine, a well-known antioxidant and regulator of inflammation, was investigated here using the sera from both girls and boys with ASD as well as their siblings and parents. Previous reports regarding taurine serum concentrations in ASD from various laboratories have been controversial. To address the potential role of taurine in ASD, we collected sera from 66 children with ASD (males: 45; females: 21, age 1.5–11.5 years, average age 5.2 ± 1.6) as well as their unaffected siblings (brothers: 24; sisters: 32, age 1.5–17 years, average age 7.0 ± 2.0) as controls of the children with ASD along with parents (fathers: 49; mothers: 54, age 28–45 years). The sera from normal adult controls (males: 47; females: 51, age 28–48 years) were used as controls for the parents. Taurine concentrations in all sera samples were measured using high performance liquid chromatography (HPLC) using a phenylisothiocyanate labeling technique. Taurine concentrations from female and male children with ASD were 123.8 ± 15.2 and 145.8 ± 8.1 μM, respectively, and those from their unaffected brothers and sisters were 142.6 ± 10.4 and 150.8 ± 8.4 μM, respectively. There was no significant difference in taurine concentration between autistic children and their unaffected siblings. Taurine concentrations in children with ASD were also not significantly different from their parents (mothers: 139.6 ± 7.7 μM, fathers: 147.4 ± 7.5 μM). No significant difference was observed between adult controls and parents of ASD children (control females: 164.8 ± 4.8 μM, control males: 163.0 ± 7.0 μM). However, 21 out of 66 children with ASD had low taurine concentrations (<106 μM). Since taurine has anti-oxidant activity, children with ASD with low taurine concentrations will be examined for abnormal mitochondrial function. Our data imply that taurine may be a valid biomarker in a subgroup of ASD.


Taurine ASD Mitochondrial dysfunction Antioxidant 



Autistic spectrum disorder




High performance liquid chromatography



This work was supported by the Office for People with Developmental Disabilities, Albany, NY. We are thankful to Dr. William Levis for discussing the research and reviewing this manuscript.


  1. Aldred S, Moore KM, Fitzgerald M, Waring RH (2003) Plasma amino acid levels in children with autism and their families. J Autism Dev Disord 33(1):93–97CrossRefPubMedGoogle Scholar
  2. American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders: DM5, 5th edn. Washington, DCCrossRefGoogle Scholar
  3. Arnold GL, Hyman SL, Mooney RA, Kirby RS (2003) Plasma amino acids profiles in children with autism: potential risk of nutritional deficiencies. J Autism Dev Disord 33(4):449–454CrossRefPubMedGoogle Scholar
  4. Ashwood P, Willis S, Van De Water J (2006) The immune response in autism: a new frontier for autism research. J Leukoc Biol 80:1–15CrossRefPubMedGoogle Scholar
  5. Bolte S, Poustka F (2002) The relation between general cognitive level and adaptive behavior domains in individuals with autism with and without co-morbid mental retardation. Child Psychiatry Hum Dev 33(2):165–172CrossRefPubMedGoogle Scholar
  6. Bourgeron T (2016) Current knowledge on the genetics of autism and propositions for future research. C R Biol 339(7–8):300–307. doi: 10.1016/j.crvi.2016.05.004 CrossRefPubMedGoogle Scholar
  7. Chauhan A, Chauhan V (2006) Oxidative stress in autism. Pathophysiology 13:171–181CrossRefPubMedGoogle Scholar
  8. Chawarska K, Shic F, Macari S, Campbell DJ, Brian J, Landa R, Hutman T, Nelson CA, Oznoff S, Tager-Flusberg H, Young GS (2014) 18-month predictors of later outcomes in younger siblings of children with autism spectrum disorder: a baby siblings research consortium study. J Am Acad Child Adolesc Psychiatry 53(12):1317–1327CrossRefPubMedPubMedCentralGoogle Scholar
  9. Cohen IL (2003) Criterion-related validity of the PDD Behavior Inventory. J Autism Dev Disord 33(1):47–53CrossRefPubMedGoogle Scholar
  10. Cohen IL, Schmidt-Lackner S, Romanczyk R, Sudhalter V (2003) The PDD Behavior Inventory: a rating scale for assessing response to intervention in children with pervasive developmental disorder. J Autism Dev Disord 33(1):31–45CrossRefPubMedGoogle Scholar
  11. Cohen IL, Liu X, Hudson M, Gillis J, Cavalari RNS, Romanczyk RG, Karmel BZ, Gardner JM (2016) Using the PDD Behavior Inventory as a level 2 screener: a classification and regression trees analysis. J Autism Dev Disord 46:3006–3022CrossRefPubMedGoogle Scholar
  12. Erickson CA, Early M, Stigler KA, Wink LK, Mullett JE, McDougle CJ (2011) An open-label naturalistic pilot study of acamprosate in youth with autistic disorder. J Child Adolesc Psychopharmacol 21(6):565–569CrossRefPubMedPubMedCentralGoogle Scholar
  13. Frye RE, Rossignol DA (2011) Mitochondrial dysfunction can connect the diverse medical symptoms associated with autism spectrum disorders. Pediatr Res 69(5):41R–47RCrossRefPubMedPubMedCentralGoogle Scholar
  14. Gaugler T, Klei L, Sanders S, Bodea C, Goldberg AP, Lee AB, Mahajan M, Manaa D, Pawitan Y, Reicher J, Ripke S, Sandin S, Sklar P, Svantesson O, Reichenberg A, Hultman CM, Devlin B, Roeder K, Buxbaum JD (2014) Most genetic risk for autism resides with common variation. Nat Genet 46:881–885CrossRefPubMedPubMedCentralGoogle Scholar
  15. Geier DA, Kern JK, Garver CR, Adams JB, Audhya T, Geier MR (2009) A prospective study of transsulfuration biomarkers in autistic disorders. Neurochem Res 34:386–393CrossRefPubMedGoogle Scholar
  16. Geschwind DH, State MW (2015) Gene hunting in autism spectrum disorder: on the path to precision medicine. Lancet Neurol 14(11):1109–1120CrossRefPubMedPubMedCentralGoogle Scholar
  17. Ghabizadeh A (2013) Increased glutamate and homocysteine and decreased glutamine levels in autism: a review and strategies for future studies of amino acids in autism. Dis Markers 35(5):281–186CrossRefGoogle Scholar
  18. Giulivi C, Zhang YF, Omanska-Klusek A, Ross-Inta C, Wong S, Herts-picciotto I, Tassone F, Pessah IN (2011) Mitochondrial dysfunction in autism. JAMA 304(21):2389–2396CrossRefGoogle Scholar
  19. Hampson DR, Blatt GJ (2015) Autism spectrum disorders and neuropathology of the cerebellum. Front Neurosci 9:1–16CrossRefGoogle Scholar
  20. Huxtable R (1999) Expanding the circle 1975–1999: Sulfur biochemistry and insight on the biological functions of taurine. Adv Exp Med Biol 483:1–25Google Scholar
  21. Jong CJ, Azuma J, Schaffer SW (2012) Mechanism underlying the antioxidant activity of taurine: prevention of mitochondrial oxidant production. Amino Acids 42:2223–2232CrossRefPubMedGoogle Scholar
  22. Junyent F, Utrera J, Romero R, Pallas M, Camins A, Duque D, Auladell C (2009) Prevention of epilepsy by taurine treatment in mice experimental model. J Neurosci Res 87:1500–1508CrossRefPubMedGoogle Scholar
  23. Kern JK, Geier DA, Adams JB, Garver CR, Audhya T, Geier MR (2011) A clinical trial of glutathione supplementation in autism spectrum disorders. Med Sci Monit 17(12):CR677–CR682CrossRefPubMedPubMedCentralGoogle Scholar
  24. Lord C, Rutter M, Le Couteur A (1994) Autism diagnostic interview-a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. J Autism Dev Disord 24:659–685CrossRefPubMedGoogle Scholar
  25. Lord C, Risi S, Lambrecht L, Cook EH, Leventhal BL, DiLavore PC, Pickeles A, Rutter M (2000) The autism diagnostic observation schedule-generic: a standard measure of social and communication deficits associated with the spectrum of autism. J Autism Dev Disord 30:205–223CrossRefPubMedGoogle Scholar
  26. Mavel S, Nadal-Desbarats L, Blasco H, Bonnet-Brilhault F, Barthelemy C, Montigny F, Sarda P, Laumonnier F, Vourc’h P, Andres CR, Emond P (2013) 1H-13C NMR-based urine metabolic profiling in autism spectrum disorders. Talanta 114:95–102CrossRefPubMedGoogle Scholar
  27. Ming X, Stein TP, Barnes V, Rhodes N, Guo L (2012) Metabolic perturbance in autism spectrum disorders: a metabolomics study. J Preteome Res 11(12):5856–5862CrossRefGoogle Scholar
  28. Moreno H, Borjas L, Arrieta A, Saez L, Prassad A, Estevez J, Bonilla E (1992) Clinical heterogeneity of the autistic syndrome: a study of 60 families. Investig Clin 33(1):13–31Google Scholar
  29. Moreno-Fuenmayer H, Borjas L, Arrieta A, Valera V, Socorro-Candanoza L (1996) Plasma excitatory amino acids in autism. Investig Clin 37(2):113–128Google Scholar
  30. Nakagawa Y, Chiba K (2016) Involvement of neuroinflammation during brain development in social cognitive deficits in autism spectrum disorder and schizophrenia. J Pharmacol Exp Ther 358(3):504–515CrossRefPubMedGoogle Scholar
  31. Naviaux JC, Schuchbauer MA, Li K, Wang L, Robrough VB, Powell SB, Naviaux RK (2014) Reversal of autism-like behaviors and metabolism in adult mice with single-dose antipuinergic therapy. Transl Psychiatry 4:e400CrossRefPubMedPubMedCentralGoogle Scholar
  32. Oliveira G, Diogo L, Ganzina M, Garcia P, Ataide A, Marques C, Miguel T, Borges L, Omcemte AM, Oliveira CR (2005) Mitochondrial dysfunction in autism spectrum disorders: a population-based study. Dev Med Child Neurol 47:185–189CrossRefPubMedGoogle Scholar
  33. Onore C, Careaga M, Ashwood P (2012) The role of immune dysfunction in the pathophysiology of autism. Brain Behav Immun 26:383–392CrossRefPubMedGoogle Scholar
  34. Ozonoff S, Young GS, Carter A et al (2011) Recurrence risk for autism spectrum disorders: a baby siblings research consortium study. Pediatrics 128:e488–e495PubMedPubMedCentralGoogle Scholar
  35. Park E, Quinn MR, Wright CE, Schuller-Levis GB (1993) Taurine chloramine inhibits the synthesis of nitric oxide and the release of tumor factor in activated RAW 264.7 cells. J Leukoc Biol 54:119–124PubMedGoogle Scholar
  36. Park E, Schuller-Levis GB, Quinn MR (1995) Taurine chloramine inhibits production of nitric oxide and TNF-α in activated RAW 264.7 cells by mechanisms that induce transcriptional and translational events. J Immunol 154:4778–4784PubMedGoogle Scholar
  37. Park E, Alberti J, Quinn MR, Schuller-Levis GB (1998) Taurine chloramine inhibits the production of superoxide anion, IL-6 and IL-8 in activated human polymorphonuclear leukocytes. In: Schaffer S, Lombardini JB, Huxtable RJ (eds) Taurine 3 cellular and regulatory mechanisms. Plenum Press, New York, pp 177–182Google Scholar
  38. Park E, Jia J, Quinn MR, Schuller-Levis G (2002) Taurine chloramine inhibits lymphocyte proliferation and decreases cytokine production in activated human leukocytes. Clin Immunol 102:179–184CrossRefPubMedGoogle Scholar
  39. Park E, Park SY, Dobkin C, Schuller-Levis G (2014) Development of a novel cysteine sulfinic acid decarboxylase knockout mouse: dietary taurine reduces neonatal mortality. J Amino Acids 2014:346809CrossRefPubMedPubMedCentralGoogle Scholar
  40. Parvez S, Tabassum H, Banerjee BD, Raisuddin S (2008) Taurine prevents tamoxifen-induced mitochondrial oxidative damage in mice. Basic Clin Pharmacol Toxicol 102:382–387CrossRefPubMedGoogle Scholar
  41. Patterson PH (2011) Maternal infection and immune involvement in autism. Trends Mol Med 17:389–394CrossRefPubMedPubMedCentralGoogle Scholar
  42. Rossignol DA, Frye RE (2012) Mitochondrial dysfunction in autism spectrum disorders: a systematic review and meta-analysis. Mol Psychiatry 17(3):290–314CrossRefPubMedGoogle Scholar
  43. Sandin S, Lichtenstein P, Kuja-Halkola R, Larsson H, Hultman CM, Reichenberg A (2014) The familial risk of autism. JAMA 311(17):1770–1777CrossRefPubMedPubMedCentralGoogle Scholar
  44. Schuller-Levis GB, Park E (2003) Taurine: new implications for an old amino acid. FEMS Microbiol Lett 226:195–202CrossRefPubMedGoogle Scholar
  45. Schuller-Levis G, Park E (2006) Is taurine a biomarker? Adv Clin Chem 41:1–21CrossRefPubMedGoogle Scholar
  46. Schuller-Levis G, Gordon RE, Park E, Pendino KJ, Laskin D (1995) Taurine protects rat bronchioles from acute ozone-induced lung inflammation and hyperplasia. Exp Lung Res 21:877–888CrossRefPubMedGoogle Scholar
  47. Schuller-Levis G, Gordon R, Wang C, Park S, Park E (2009) Protection of bleomycin-induced fibrosis and inflammation by taurine. Int Immunopharmacol 9:971–977CrossRefPubMedGoogle Scholar
  48. Sealey LA, Hughes BW, Sriskanda AN, Guest JR, Gibson AD, Johnson-William L, Pace DG, Bagasra O (2016) Environmental factors in the development of autism spectrum disorders. Environ Int 88:288–298CrossRefPubMedGoogle Scholar
  49. Shetewy A, Shimada-Takaura K, Warner D, Jong CJ, Mehdi AB, Alexeyev M, Takahashi K, Schaffer SW (2016) Mitochondrial defects associated with β-alanine toxicity: relevance to hyper-beta-alaninemia. Mol Cell Biochem 416(1–2):11–22CrossRefPubMedPubMedCentralGoogle Scholar
  50. Shimada K, Jong CJ, Takhashi K, Schaffer SW (2014) Role of ROS production and turnover in the antioxidant acidity of taurine. Adv Exp Med Biol 803:581–596CrossRefGoogle Scholar
  51. Singh K, Connors SL, Macklin EA, Smith KD, Fahey JW, Talalay P, Zimmerman AW (2014) Sulforaphane treatment of autism spectrum disorder (ASD). Proc Natl Acad Sci U S A 111(43):15550–15555CrossRefPubMedPubMedCentralGoogle Scholar
  52. Sturman J (1993) Taurine in development. Physiol Rev 73(1):119–147PubMedGoogle Scholar
  53. Sweeten TL, Bowyer SL, Posey DJ et al (2003) Increased prevalence of familial autoimmunity in probands with pervasive developmental disorders. Pediatrics 112(5):e420CrossRefPubMedGoogle Scholar
  54. Tu WJ, Chen H, He J (2012) Application of LC/MS/MS analysis of plasma amino acids profiles in children with autism. J Clin Biochem Nutr 51(3):248–249PubMedPubMedCentralGoogle Scholar
  55. Vargas DL, Nascimbene C, Krishnan C, Zimmerman AW, Pardo CA (2005) Neuroglial activation and neuroinflammation in the brain of patient with autism. Ann Neurol 57:67–81CrossRefPubMedGoogle Scholar
  56. Wegiel J, Flory M, Kuchna I, Norwicki K, Ma SY, Wegiel J, Frackowiak J, Mazur-Kolecka B, Wierzba-Bobrowicz T, London E, Wisniewski T, Hof PR, Brown WT (2015) Neuronal nucleus and cytoplasm volume deficit in children with autism and volume increase in adolescents and adults. Acta Neuropathol Commun 3:2CrossRefPubMedPubMedCentralGoogle Scholar
  57. White JF (2003) Intestinal pathophysiology in Autism. Exp Biol Med (Maywood) 228(6):639–649CrossRefGoogle Scholar
  58. Wink LK, Adams R, Wang Z, Klaunig JE, Plawecki MH, Posey DJ, McDougle CJ, Erickson CA (2016) A randomized placebo-controlled pilot study of N-acetylcysteine in youth with autism spectrum disorder. Mol Autism 7:26. doi: 10.1186/s13229-016-0088-6. Ecollection 2016CrossRefPubMedPubMedCentralGoogle Scholar
  59. Yap IK, Angley M, Veselkov KA, Holmes E, London JC, Nicholson JK (2010) Uninary metabolic phenotyping differentiates children with autism from their unaffected siblings and age-matched controls. J Proteome Res 9(6):3996–4004CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2017

Authors and Affiliations

  1. 1.Departments of Developmental NeurobiologyNY State Institute for Basic Research in Developmental DisabilitiesStaten IslandUSA
  2. 2.Department of PsychologyNY State Institute for Basic Research in Developmental DisabilitiesStaten IslandUSA
  3. 3.Division of Hematology/Oncology, Division of Research, Department of MedicineStaten Island University Hospital-Northwell HealthStaten IslandUSA
  4. 4.Department of Infant DevelopmentNY State Institute for Basic Research in Developmental DisabilitiesStaten IslandUSA
  5. 5.Department of Human GeneticsNY State Institute for Basic Research in Developmental DisabilitiesStaten IslandUSA

Personalised recommendations